Glutathione injection recalled Class I over microbial contamination

The Food and Drug Administration has recorded a Class I recall of an injectable glutathione product after it was found to be microbially contaminated — a defect in a drug that is supposed to be sterile and is injected into the body [s1]. The agency logged the action in its enforcement database on 28 October 2026 and assigned it the most serious recall classification, the category reserved for defects that could cause serious injury or death [s1].

What is affected

The recall covers Glutathione Injection — formulated with glutathione, ascorbic acid (vitamin C), sodium hydroxide and bacteriostatic water — at a strength of 200 mg/mL in a 10 mL multi-dose vial, prescription-only and labelled for subcutaneous (under-the-skin) use [s1]. The recalling firm is Greenwich Rx of Tomball, Texas, and the action covers 4,319 vials distributed nationwide across the United States, spanning twelve lots [s1]. The company began the recall itself on 1 October 2026, making this a voluntary, firm-initiated action announced by press release, and the FDA records its status as ongoing [s1]. The agency assigned the Class I classification on 27 October and logged the enforcement report the following day, so the public record of how serious the defect is reached the database roughly four weeks after the firm first acted [s1]. The twelve affected lots carry beyond-use dates running from early October into late November 2026, the window during which the product would ordinarily still have been in use [s1].

Why microbial contamination of a sterile injectable matters

The enforcement record states the reason plainly: microbial contamination of sterile products [s1]. The phrase carries its weight in the word "sterile." A drug meant to be free of living microorganisms, then injected, bypasses the skin and gut — the body's main barriers against infection. If bacteria or fungi are present in the vial, injecting it can introduce them directly into tissue or the bloodstream, where they can cause local abscesses or a systemic, potentially life-threatening infection. That is why a sterility failure in an injectable draws the agency's top recall tier, even when no specific harm has yet been reported.

Two features of this product raise the stakes further. It is a multi-dose vial, meaning a single container is entered more than once, so contamination can be delivered across several doses and, potentially, several patients. And it is bacteriostatic — the formulation includes an agent intended to hold back microbial growth — which makes a finding of contamination despite that safeguard the kind of result regulators treat as a signal rather than a fluke.

The wider context

Glutathione is an antioxidant the body makes naturally, and injectable versions are compounded and marketed for a range of uses — including cosmetic "skin-brightening" — that sit well outside anything the FDA has approved glutathione injection to do. This recall is a manufacturing-quality action about one contaminated product, and says nothing in itself about those claims; but a sterile injectable sold into the wellness market is exactly the kind of product where a quality lapse can reach people who did not need an injection in the first place. The enforcement record documents the contamination and the recall, not any clinical outcome [s1].

What to watch

Because the action is ongoing, the practical questions are whether distribution is fully traced and whether any infections surface among people who received doses from the affected lots [s1]. Anyone who has been given an injection from this product should rely on the recall notice and their clinician or pharmacy to confirm whether their vial is among those listed, rather than on the product label alone.

Red flags: redness, swelling, warmth or pus at an injection site, or fever and chills after receiving an injection, warrant prompt medical attention, as these can signal infection. This article describes a regulatory enforcement action and is not medical advice.